



For Immediate Release

**Vaxart to Present at the Sachs Associates 8th Annual European Life Sciences
CEO Forum & Exhibition in Zurich on Wednesday, March 4, 2015**

SOUTH SAN FRANCISCO, Calif., February 26, 2015 — Vaxart, Inc., a privately held, clinical-stage company developing vaccines that are administered by tablet rather than by injection, today announced that Vaxart CEO Wouter Latour, MD, will present a corporate overview at the Sachs Associates 8th Annual European Life Science CEO Forum & Exhibition in Zurich on Wednesday, March 4, 2015 at 11:45 a.m. Central European Time. Dr. Latour will also take part in a panel discussion on vaccines at 10:45 a.m. Central European Time on the same day, and he will be available to participate in one-on-one meetings during the forum.

About Vaxart

Vaxart is a privately held company developing oral recombinant vaccines based on its proprietary delivery platform. The Vaxart platform is suitable for delivering any protein antigen such as those used in currently marketed influenza, hepatitis B and human papilloma virus (HPV) vaccines. By eliminating needles, Vaxart's temperature-stable tablet vaccines offer a wide range of advantages such as: convenience, acceptance, self-administration, reduced cold chain requirements, reduced medical waste, and rapid and scalable manufacturing. For more information, please visit www.vaxart.com.

###

CONTACT:

Kimberly Minarovich
Burns McClellan, 212-213-0006
kminarovich@burnsmc.com